Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-administration of recombinant zoster vaccine with influenza or COVID-19 vaccination
ISRCTN26495549Phase 4Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 4, randomised, double-blind trial of Zoster vaccine recombinant, RH109 and MF59-adjuvanted quadrivalent influenza vaccine in herpes zoster (HZ), influenza and coronavirus disease 2019 (COVID-19) (5 arms), sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Started Oct 2023; status: completed.
02
Drugs
Zoster vaccine recombinantRH109MF59-adjuvanted quadrivalent influenza vaccine
03
Conditions
herpes zoster (HZ)influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ISRCTN26495549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN26495549.